Země: Austrálie
Jazyk: angličtina
Zdroj: Department of Health (Therapeutic Goods Administration)
Canakinumab, Quantity: 150 mg
Novartis Pharmaceuticals Australia Pty Ltd
Canakinumab
Injection, powder for
Excipient Ingredients: sucrose; histidine; histidine hydrochloride monohydrate; polysorbate 80; dilute hydrochloric acid
Subcutaneous
1, 4
(S4) Prescription Only Medicine
Ilaris is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children aged 2 years or older including: Familial Cold Autoinflammatory Syndrome (FCAS) /Familial Cold Urticaria (FCU); Muckle-Wells Syndrome (MWS); Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA). Ilaris is indicated for the treatment of active Systemic Juvenile Idiopathic Arthritis (sJIA) in patients aged 2 years or older.
Visual Identification: White solid lyophilisate; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 36 Months; Container Temperature: Store at 2 to 8 degrees Celsius
Registered
2010-05-10